• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

J&J approaches Actelion

November 28, 2016 By Sarah Faulkner

J&J approaches ActelionJohnson & Johnson (NYSE:JNJ) is reportedly in preliminary discussions to buy Actelion Pharmaceuticals (VTX:ATLN) in a deal estimated to be as high as $247 (250 Swiss francs) per share, although the European biotech said there is no guarantee the deal will go through.

J&J’s CEO Alex Gorsky said this year that the company is interested in deals to expand its medical device and pharmaceuticals segments, according to Reuters, evidenced by its $4.33 billion buy of Abbott Laboratories’ eye care business in September.

Allschwil, Switzerland-based Actelion’s drugs, Opsumit and Uptravi, treat high pressure in blood vessels to the lungs. Analysts forecast the 2 could generate more than $4.6 billion in 2020 sales, up from an estimated $1.4 billion this year. The company’s pipeline focuses on treatments for rare diseases, making it an attractive takeover target for buyers on the lookout for candidates with less pricing pressure.

Actelion shares soared on Friday, up +19% to a peak of 187.70 Swiss francs, which put the company at a value of $20 billion. J&J shares finished up +1% at $144.13 apiece.

Actelion co-founder and CEO Jean-Paul Clozel has repeatedly asserted that he wants the company to remain independent, like in 2011 when he allied shareholders against an investor’s campaign to put the firm up for sale. Since then, Actelion’s shares have more than tripled. The desire to remain independent in combination with the high value of recent deals in the pharma sector will drive up the takeover price for J&J, analysts told Reuters.

If J&J fails to make a deal, it is likely another company such as Sanofi (NYSE:SNY) or Novartis (NYSE:NVS) will step in and make a bid, analysts predicted. Neither company has made an official statement about its interest in Actelion.

Some, like Bank Vontobel analyst Stefan Schneider, doubted any deal will go through at all, especially if the buyer shows interest in messing with Clozel’s pipeline. “We don’t see how the CEO would part from the pipeline where he sees the value for Actelion to transform into the first European large-cap biotech company,” Schneider told Reuters.

Others speculated that as Clozel gets older he may become more interested in handing over the reins, especially if a buyer agrees to maintain the company’s presence in Basel alongside pharma giants Roche (PINK:RHHBY) and Novartis.

“Even when Clozel has always made the case for independence, it’s possible a stock price at its zenith, combined with his 61 years, could prompt a change of heart,” Zuercher Kantonalbank analyst Michael Nawrath told the news outlet.

Filed Under: Featured, Mergers & Acquisitions, Respiratory, Wall Street Beat Tagged With: Actelion Pharmaceuticals, johnsonandjohnson, Novartis, Roche, Sanofi-Aventis

IN CASE YOU MISSED IT

  • Shareholder lawsuit over BD’s Alaris pumps recall moves forward
  • Embecta stock soars on first full-quarter results after BD spinoff
  • Abbott will spend $450M to up FreeStyle Libre production in Ireland
  • Better Therapeutics Q2 beats Street as it prepares to submit diabetes therapy for FDA review
  • Study backs Fluidx embolic device for vessel filling

Primary Sidebar

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Need Drug Delivery Business News in a minute? We Deliver!
Drug Delivery Enewsletters get you caught up on all the mission critical news you need in med tech. Sign up today.

Signup for the newsletter

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing & Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts
Add us on FacebookFollow us on TwitterConnect with us on LinkedIn

Copyright © 2022 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Advertise | Privacy Policy | RSS